其他

港股IPO招股书披露先例 · 6 家公司,6 项

此类事项指不属于其他常见类别的披露事项,多为内控顾问审阅中发现的内部控制缺陷或管理制度有待建立之处。招股书一般于风险因素、业务、概要及财务资料等章节披露,通常说明审阅范围与发现、该等缺陷未对集团业务运营及财务表现造成重大不利影响,并载明公司已采纳建议的整改措施、经跟进复核后不存在重大未决问题,部分案例中董事认为经加强的内控措施足以确保今后合规,并经保荐人认可。

合规类事项自 2026 年 8 月 24 日起递交的文件开始收录。

2026-09-28PHIP合规确认
安徽希磁科技股份有限公司Anhui Sinomags Technology Co., Ltd

资本储备弥补累计亏损及分红能力确认

As confirmed by our PRC Legal Advisor, capitals reserves can be used for making up for accumulated losses in accordance with applicable PRC laws.

Financial Information · 第 256 页

As of May 31, 2026, our Company had capital reserves of RMB2,405.6 million and accumulated losses of RMB1,276.7 million, respectively.

Financial Information · 第 256 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-09-21Prospectus合规确认
深圳市景旺电子股份有限公司Shenzhen Kinwong Electronic Co., Ltd.03228.HK

股息分配须先弥补累计亏损并提取法定公积金

As confirmed by our PRC Legal Advisor, according to relevant PRC laws, any future net profit that we make will have to be first applied to make up for our historically accumulated losses, after which we will be obliged to allocate 10% of our net profit to our statutory common reserve fund until such fund has reached more than 50% of our registered capital.

Financial Information · 第 242 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-31Application Proof不合规事项
普莱医药(江苏)股份有限公司ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.

内控顾问发现内部控制缺陷

The Internal Control Consultant performed the Internal Control Review in November and December 2025, identified internal control deficiencies and provided recommendation accordingly.

Business · 第 220 页

These deficiencies primarily concerned internal control policies with respect to information system control, monitoring of software usage on employees’ computers, monitoring of regulatory filing process, and other deficiencies in relation to the Company’s governance structure and policies required for a listed company according to the Listing Rules, none of which had resulted in any material adverse impact on the Group’s business operation and financial performance.

Business · 第 220 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof不合规事项

内控审查发现部分管理制度待建立

The main issues identified during the Internal Control Review in relation to the review scope include that information disclosure management policy and related party transaction management policy need to be established according to the latest Listing Rules.

Business · 第 217 页

We had thereafter adopted the recommended internal control measures and rectified the internal control findings identified.

Business · 第 217 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-08-28Application Proof合规确认
维眸生物科技(浙江)股份有限公司VivaVision Biotech (Zhejiang) Co., Ltd.

累计亏损下利润分配受限于公司法规定

In view of our accumulated losses, as advised by our PRC Legal Advisers, according to the relevant PRC laws and regulations and the Articles of Association, we shall not declare or pay dividend until the accumulated losses are covered by our after-tax profits and sufficient statutory common reserve are drawn in accordance with the relevant laws and regulations.

Financial Information · 第 267 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us